US healthcare giant Johnson & Johnson announced that the US Food and Drug Administration (FDA) approved Rybrevant Fasbro ...

US biotech Cytokinetics (Nasdaq: CYTK) has secured the first global approval for its cardiac myosin inhibitor aficamten, ...

An Expert View piece looking forward to next year from the global strategy consultancy's Simon Middleton, head, Europe Life ...

California, USA-based Vistagen yesterday announced that the PALISADE-3 Phase III study of intranasal fasedienol for the acute ...

RNAi therapeutics company Alnylam Pharmaceuticals has announced the planned expansion of its manufacturing facility in Norton ...

Cambridge, USA-based CAMP4 Therapeutics has entered into a strategic research, collaboration and license agreement with UK ...

A clinical-stage biotechnology company headquartered in Schlieren (Zurich), Switzerland. The company develops locally acting ...

US biopharma Insmed Incorporated has announced that the Phase IIb BiRCh study of brensocatib in chronic rhinosinusitis ...

US biotech VYNE Therapeutics has agreed to merge with privately held Yarrow Bioscience in an all-stock transaction, pivoting ...

Japanese drugmaker Takeda has announced positive topline results for two pivotal Phase III studies of zasocitinib (TAK-279), ...

UK pharma major GSK yesterday announced that the US Food and Drug Administration (FDA) has approved Exdensur ...

US biotech Incyte yesterday revealed that the European Commission (EC) has approved Minjuvi (tafasitamab) in combination with ...